

genAP

Efficient clinical analysis of
DNA sequencing data

Morten C. Eike

Post doc

Dep of Medical Genetics
Oslo University Hospital




UNIVERSITY
OF OSLO




The Research Council
of Norway


Genetic testing



High-throughput DNA sequencing (HTS)




Data increase




\$1.000 genome - \$1.000.000 interpretation

Challenges


- Large amounts of sensitive data
- Complex interpretation process



genAP Norwegian clinical genetic Analysis Platform



Interpretation



genAP interpreter

The screenshot displays the genAP interpreter interface for a variant analysis. The user is logged in as John Doe (JD). The current analysis is titled "BRCA_S1-HBOC-v00" and has a status of "Not started". The process is shown as a sequence of steps: VarDB, Frequency, External DB, References (13), Prediction, and Classification. The "References" step is currently active, showing a table of references for three BRCA2 variants.


Gene	Variant	ExAC	1000G	Comment	Checked
BRCA2	c.7242A>G	AFR:0.2119 AMR:0.1795 EAS:0.3845 FIN:0.2362 NFE:0.2142 OTH:0.2274 SAS:0.2168	G:0.2452 AMR:0.2000 ASN:0.3900 EUR:0.2200 AA:0.2077 EA:0.2133	<input type="text"/>	<input type="checkbox"/>
BRCA2	c.6513G>C	AFR:0.9247 AMR:0.9967 EAS:0.9999 FIN:1.0000 NFE:0.9995 OTH:0.9989 SAS:0.9998	AMR:0.9900 AA:0.9287 EA:0.9994	<input type="text"/>	<input type="checkbox"/>
BRCA2	c.2T>G	AMR:0.0001		<input type="text"/>	<input type="checkbox"/>

- Stepwise process
- Evaluate annotation
- Evaluate references
- Summary and clinical classification


Rules-based interpretation


Pathogenic

Examples



Benign






-rules from ACMG

Classification	Rule	Colour
Pathogenic	(i) 1 Very strong (PVS1) AND (a) ≥ 1 Strong (PS1–PS4) OR (b) ≥ 2 Moderate (PM1–PM6) OR (c) 1 Moderate (PM1–PM6) and 1 supporting (PP1–PP5) OR (d) ≥ 2 Supporting (PP1–PP5)	
	(ii) ≥ 2 Strong (PS1–PS4) OR	
	(iii) 1 Strong (PS1–PS4) AND (a) ≥ 3 Moderate (PM1–PM6) OR (b) 2 Moderate (PM1–PM6) AND ≥ 2 Supporting (PP1–PP5) OR (c) 1 Moderate (PM1–PM6) AND ≥ 4 supporting (PP1–PP5)	
Likely pathogenic	(i) 1 Very strong (PVS1) AND 1 moderate (PM1–PM6) OR	
	(ii) 1 Strong (PS1–PS4) AND 1–2 moderate (PM1–PM6) OR	
	(iii) 1 Strong (PS1–PS4) AND ≥ 2 supporting (PP1–PP5) OR	
	(iv) ≥ 3 Moderate (PM1–PM6) OR	
	(v) 2 Moderate (PM1–PM6) AND ≥ 2 supporting (PP1–PP5) OR	
	(vi) 1 Moderate (PM1–PM6) AND ≥ 4 supporting (PP1–PP5)	
Benign	(i) 1 Stand-alone (BA1) OR	
	(ii) ≥ 2 Strong (BS1–BS4)	
Likely benign	(i) 1 Strong (BS1–BS4) and 1 supporting (BP1–BP7) OR	
	(ii) ≥ 2 Supporting (BP1–BP7)	
Uncertain significance	(i) Other criteria shown above are not met OR	
	(ii) the criteria for benign and pathogenic are contradictory	


Literature reference evaluation

Reference evaluation
 Selected reference: Van Hausen et al 2012 (PMID:23709336)
 Variant: BRCA1 c.38T>C 


Category	Evaluation	ACMG	Score
Relevance	<input type="radio"/> Is the reference relevant?	<input checked="" type="radio"/> Yes <input type="radio"/> Indirectly <input type="radio"/> No <input type="radio"/> Ignore	
Conclusion	<input type="radio"/> Variant classification	<input checked="" type="radio"/> Pathogenic <input type="radio"/> VUS <input type="radio"/> Neutral	
<input checked="" type="checkbox"/> Segregation	<input type="radio"/> Variant segregates with disease?	<input checked="" type="radio"/> Strong <input type="radio"/> Moderate <input type="radio"/> Weak <input type="radio"/> No	<input checked="" type="radio"/> PSX <input type="radio"/> 3
<input type="checkbox"/> Protein	<input type="radio"/> Abnormal protein function?	<input type="radio"/> ++ <input type="radio"/> + <input type="radio"/> - <input type="radio"/> --	<input type="radio"/> ... <input type="radio"/> ...
<input checked="" type="checkbox"/> RNA	<input type="radio"/> Abnormal splicing/protein expression?	<input type="radio"/> ++ <input checked="" type="radio"/> + <input type="radio"/> - <input type="radio"/> --	<input checked="" type="radio"/> PMX <input type="radio"/> 2
<input type="checkbox"/> In silico	<input type="radio"/> Results of prediction tools?	<input type="radio"/> Pathogenic <input type="radio"/> Neutral <input type="radio"/> Select tool...	<input type="radio"/> ... <input type="radio"/> ...
<input type="checkbox"/> Population	<input type="radio"/> Increased in affecteds or present in documented healthy individual?	<input type="radio"/> RR>5 <input type="radio"/> Affecteds <input type="radio"/> Healthy	<input type="radio"/> ... <input type="radio"/> ...
Gene coverage	<input type="radio"/> >90% of gene sequenced?	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> 0
Age of evidence (auto)	<input type="radio"/> Reference <10 years?	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> 0
Overall quality	<input type="radio"/> ?	<input type="radio"/> Poor <input type="radio"/> Lacking <input type="radio"/> Passable <input checked="" type="radio"/> Good <input type="radio"/> Excellent	<input type="radio"/> 2
Normalised score			<input checked="" type="radio"/> +4
Conclusion:	<input type="radio"/> High quality evidence?	<input checked="" type="radio"/> Yes <input type="radio"/> No	
<input type="text" value="[Comments/excerpt of article]"/> <input checked="" type="radio"/> PSX <input type="radio"/> PMX			
<input type="button" value="Finish"/>			

Rules-based answer

Collect and weigh data:
- annotation
- reference evaluation



Apply weighted rules



Suggested classification with summary

Response from test users:

“When is it available??”

Status

- In place
 - Automated sequence processing and annotation
 - Working prototype of interpreter on TSD 2.0 (wxPython)
- In development
 - Complete rewrite of the interpreter (WebUI+REST API)
 - New rules engine
 - Beta by December 2015
- Test access
 - Medicloud

Some of the people involved

- Project management:
 - Thomas Grünfeld (OUS)
- Steering group:
 - Dag Undlien (OUS)
 - Margunn Aanestad (IFI)
 - Hans Eide (USIT)
 - Sissel Jor (OUS)
- Legal issues:
 - Heidi Bentzen (JUR)
 - Marit Stubø (JUR)
- Clinical analyses:
 - Morten C. Eike (OUS)
 - Eidi Nafstad (OUS)
- System development:
 - Tony Håndstad (OUS)
 - Espen Skorve (IFI)
 - Svein Tore Seljebotn (OUS)
 - Hugues Fontenelle (OUS)
 - Hallvard Lærum (OUS)
 - Gard Thomassen (USIT)
 - Vegard B. Havdal (Trevis)

Contact:

m.c.eike@medisin.uio.no